Page 93 - Haematologica - Vol. 105 n. 6 - June 2020

PRIMA-1Met and AZA combination in TP53-mutant MDS/AML
25. Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N. Strong synergy with APR-246 and DNA- damaging drugs in primary cancer cells from patients with TP53 mutant High- Grade Serous ovarian cancer. J Ovarian Res 2016;9(1):27.
26. Ali D, Jönsson-Videsäter K, Deneberg S, et al. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur J Haematol 2011;86(3): 206-215.
27. Tessoulin B, Descamps G, Moreau P, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood 2014;124(10): 1626-1636.
28. Sobhani M, Abdi J, Manujendra SN, Chen C, Chang H. PRIMA-1Met induces apopto- sis in Waldenström’s Macroglobulinemia cells independent of p53. Cancer Biol Ther 2015;16(5):799-806.
29. Sallman D. Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with <em>TP53 </Em>mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). ASH; Blood. 2018;132 (Supplement 1):3091.
30. Lehmann S, Bykov VJN, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-
246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 2012;30(29):3633-3639.
31. Deneberg S, Cherif H, Lazarevic V, et al. An open-label phase I dose-finding study of APR-246 in hematological malignancies. Blood Cancer J 2016;6(7):e447.
32. Lainey E, Wolfromm A, Marie N, et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene 2013;32(37):4331-4342.
33. Cluzeau T, Dubois A, Jacquel A, et al. Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. Oncotarget 2014;5(12): 4384-4391.
34. Ali D, Mohammad DK, Mujahed H, et al. Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells. Br J Haematol 2016;174(1):117-126.
35. Yoshikawa N, Kajiyama H, Nakamura K, et al. PRIMA-1MET induces apoptosis through accumulation of intracellular reac- tive oxygen species irrespective of p53 sta- tus and chemo-sensitivity in epithelial ovarian cancer cells. Oncol Rep 2016;35(5):2543-2552.
36. Saha MN, Abdi J, Yang Y, Chang H. MiRNA-29a as a tumor suppressor medi-
ates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget 2016;7(6):7149-7160.
37. Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis 2018;9(5):439.
38. Lübbert M, Miller CW, Crawford L, Koeffler HP. p53 in chronic myelogenous leukemia. Study of mechanisms of differ- ential expression. J Exp Med 1988;167(3): 873-886.
39. Akashi M, Hachiya M, Osawa Y, Spirin K, Suzuki G, Koeffler HP. Irradiation Induces WAF1 Expression through a p53-indepen- dent Pathway in KG-1 Cells. J Biol Chem 1995;270(32):19181-19187.
40. Peng X, Zhang M-Q-Z, Conserva F, et al. APR-246/PRIMA-1MET inhibits thioredox- in reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis 2013;4e881.
41. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003;17(1):120-124.
42. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and over- come resistance to other small molecule inhibitors. Haematologica 2007;92(1):27-34.
haematologica | 2020; 105(6)
1551